Ventyx Biosciences' VTX3232 showed promising anti-inflammatory Phase 2 results, but financial risks remain. Click here to ...
AI-driven data center growth has exposed power supply constraints. Read why energy companies may provide the solution.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback